tiprankstipranks
Advertisement
Advertisement

AZN Stock Latest News

Roche reports FDA approval for prostate cancer companion diagnostic
The FlyRoche reports FDA approval for prostate cancer companion diagnostic
1d ago
AZN
CHRO
Truqap approved for PTEN-deficient metastatic hormone-sensitive prostate cancer
PremiumThe Fly
Truqap approved for PTEN-deficient metastatic hormone-sensitive prostate cancer
1d ago
AZN
AstraZeneca’s GRANITE Study Puts Airsupra’s Real‑World Edge Over Albuterol to the Test
PremiumCompany Announcements
AstraZeneca’s GRANITE Study Puts Airsupra’s Real‑World Edge Over Albuterol to the Test
1d ago
AZN
Analyst James Quigley Reiterates Buy on AstraZeneca, Citing Undervalued Pipeline‑Driven Growth Upside
PremiumRatings
Analyst James Quigley Reiterates Buy on AstraZeneca, Citing Undervalued Pipeline‑Driven Growth Upside
4d ago
AZN
AstraZeneca: Breast Cancer Pipeline Strength Supports Buy Rating as Sachin Jain Reiterates Unchanged 16,500 GBp Price Target
PremiumRatings
AstraZeneca: Breast Cancer Pipeline Strength Supports Buy Rating as Sachin Jain Reiterates Unchanged 16,500 GBp Price Target
5d ago
AZN
AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D
PremiumThe FlyAstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D
5d ago
AZN
Analyst Reaffirms Buy on AstraZeneca, Citing Underappreciated Non‑Oncology Growth and Blockbuster Pipeline Upside
Premium
Ratings
Analyst Reaffirms Buy on AstraZeneca, Citing Underappreciated Non‑Oncology Growth and Blockbuster Pipeline Upside
8d ago
AZN
Acting FDA head vows to block political interference, Endpoint News says
Premium
The Fly
Acting FDA head vows to block political interference, Endpoint News says
9d ago
AZN
BMY
AstraZeneca’s ASCEND Obesity Trial Completion Puts New Weight Loss Combo in Focus
PremiumCompany Announcements
AstraZeneca’s ASCEND Obesity Trial Completion Puts New Weight Loss Combo in Focus
10d ago
AZN
AstraZeneca: Late-Stage Pipeline Strength and Lung Cancer Upside Support Buy Rating and Unchanged 16,500 GBp Price Target
PremiumRatings
AstraZeneca: Late-Stage Pipeline Strength and Lung Cancer Upside Support Buy Rating and Unchanged 16,500 GBp Price Target
11d ago
AZN
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
11d ago
AZN
BMY
AstraZeneca announces additional results from Phase III Serena-6 trial
PremiumThe Fly
AstraZeneca announces additional results from Phase III Serena-6 trial
11d ago
AZN
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
PremiumThe FlyAstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
11d ago
AZN
AstraZeneca Adds Employee Scheme Shares to London Listing
Premium
Company Announcements
AstraZeneca Adds Employee Scheme Shares to London Listing
12d ago
AZN
AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
Premium
Company Announcements
AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
12d ago
AZN
AIM ImmunoTech enrolls final subject in pancreatic cancer development program
PremiumThe Fly
AIM ImmunoTech enrolls final subject in pancreatic cancer development program
12d ago
AIM
AZN
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
PremiumThe Fly
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
13d ago
AZN
Analyst Reiterates Buy on AstraZeneca, Citing Dominant Oncology Portfolio and Sustained Growth Prospects
PremiumRatings
Analyst Reiterates Buy on AstraZeneca, Citing Dominant Oncology Portfolio and Sustained Growth Prospects
13d ago
AZN
AstraZeneca Prostate Cancer Study in Russia Paused, Nudging Real‑World Data Timeline
PremiumCompany Announcements
AstraZeneca Prostate Cancer Study in Russia Paused, Nudging Real‑World Data Timeline
15d ago
AZN
AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint
PremiumThe FlyAstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint
15d ago
AZN
AstraZeneca Imfinzi combination approved in the U.S.
Premium
The Fly
AstraZeneca Imfinzi combination approved in the U.S.
16d ago
AZN
AstraZeneca Wins First U.S. Immunotherapy Combo Approval in Early Bladder Cancer
Premium
Company Announcements
AstraZeneca Wins First U.S. Immunotherapy Combo Approval in Early Bladder Cancer
16d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >